Merck’s fast-ascending kidney cancer drug hits a setback

BioPharma Dive

Welireg s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Clinical DataOncologyRead full story